Study title: Evaluation of monoclonal antibody MIB-1 in the mammary epithelium adjacent to fibroadenomas in premenopausal women treated with Tamoxifen. De Sousa JA, De Seixas MT, De Lima GR, Baracat EC, Gebrim LH. Breast Journal 7(6)()(pp 392-397), 2001 Date of Publication: 2001 2001;(6):392-397.Evaluation of monoclonal antibody MIB-1 in the mammary epithelium adjacent to fibroadenomas in premenopausal women treated with Tamoxifen. De Sousa JA, De Seixas MT, De Lima GR, Baracat EC, Gebrim LH. Breast Journal 7(6)()(pp 392-397), 2001 Date of Publication: 2001 2001;(6):392-397.
| Type of medicine: Medicines containing chemical active substances | |||||
| Therapeutic area: Neoplasms [C04] | |||||
| Brands: Please see report | |||||
| MAH holders: Please see report | |||||
| Assessment: | |||||
| Active substance: TAMOXIFEN | |||||
| ATC code: L02BA01 | |||||
| Document link: | |||||
| Document date: | |||||
| Study number: | |||||
| EudraCT number: | |||||
| Scope of study: Clinical | |||||
| Population of study subjects: | Preterm newborn Infants | Newborn infants (1 to 27 days) | Infants and toddlers (28 days to 24 months) | Children (2 to 11 years) | Adolescents (12 to 18 years) |
| - | - | - | - | - | |